NOAEL Studies
Active Ingredient
Octinoxate NOAEL Studies
INCI: ETHYLHEXYL METHOXYCINNAMATE
CAS: 5466-77-3
Raw No Observed Adverse Effect Level endpoint records grouped by source. This page does not render calculated Margin of Safety values.
SCCS_vision_codex 40 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| SCCS_vision_codex | NOAEL | =900 | mg/kg bw/day | rat | dermal | - | NOAEL study | {"dose":"Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats.","effect":"SCCS-rejected applicant NOAEL: SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 43 decrease in the absolute weight of the heart. Further, increases in the absolute weight of the pituitary were observed at the lower doses but these were not considered to be biologically significant. Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study). Dermal exposure 1st study Guideline: No guideline Species/strain: Rabbits/ New Zealand White Group size: 5/sex/group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: Not specified Route: Dermal Administration: Occ","page":43,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_001"} |
| SCCS_vision_codex | NOAEL | =1500 | mg/kg bw/day | rat | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day.","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study is considered as reliable with restrictions as the top two doses exceeded the recommended limit dose of 1000 mg/kg/day. 2nd study Guideline: Similar to OECD Test Guideline 410 Species/strain: Rats/Sprague-Dawley Group size: 5/ sex/ group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: 0, 0.5,","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_002"} |
| SCCS_vision_codex | NOAEL | =5000 | mg/kg bw/day | - | dermal | - | NOAEL study | {"dose":"This was dose dependent and appeared to be more prominent in males.","effect":"mals were sacrificed and macroscopically examined, organs were weighed, and comprehensive histopathology was performed. Results No mortalities and no treatment related systemic effects were observed. No effects were noted at necropsy in any of the tissues or organs evaluated. All animals displayed low grade epidermal proliferation. This was dose dependent and appeared to be more prominent in males. Dermal inflammatory or fibrotic responses were not significant. Conclusion Under the conditions of the study, the NOAEL for EHMC was established by the study authors at 5000 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017)","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_003"} |
| SCCS_vision_codex | NOAEL | =450 | mg/kg bw/day | - | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021;","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021; NICNAS, 2017) SCCS comment The range of investigations was consistent with the version of the OECD TG at the time the study was conducted, including gross and histopathological examination of the thyroid gland. No treatment-related changes were reported for food consumption, body weight, body weight gain or mortalities. This study is considered as reliable. A NOAEL of 450 mg/kg bw/day based on reduction of the glycogen content and shrinkage of hepatocytes at a dose of 1","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_004"} |
| SCCS_vision_codex | NOAEL | =555 | mg/kg bw/day | - | inhalation | 5 days | NOAEL study | {"dose":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks.","effect":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks. Results No mortalities were observed. Slight scaliness of the skin (attributed to the vehicle) was observed at the application sites for all animals. At the highest dose, elevated (but non- significant) serum alanine phosphatase (SAP) levels and increased relative liver weights were observed. Liver effects were not observable upon microscopic examination. There were no changes in haematological parameters. Conclusion The study investigators established the NOAEL for EHMC at 555 mg/kg bw/day. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study, exposure is not continuous…) Inhalation route No inhalation studies on EHMC could be identified.","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_006"} |
| SCCS_vision_codex | NOAEL | =1000 | mg/kg bw/day | - | - | developmental | developmental toxicity | {"dose":"Slight reduction in the body weight was observed at the highest dose.","effect":"emales during the study. Slight reduction in the body weight was observed at the highest dose. Skeletal variation was seen to be increased. Conclusion Under the study conditions, the test substance was not teratogenic up to highest tested dose of 1000 mg/kg bw/day. (SCC, 2000) SCCS comment In the Evaluation Conclusion Document (2017) this study is described in more detail (Vehicle: 5% Carboxymethylcellulose, 0.5% Benzyl-EtOH, 0.4% TWEEN 80, 0.9% NaCl), which better demonstrates the reliability of the results. A NOAEL of 1000 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity, as no effects were observed at the highest dose.","page":49,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_010"} |
| SCCS_vision_codex | NOAEL | =500 | mg/kg bw/day | - | - | developmental | reproductive toxicity | {"dose":"The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls.","effect":"the highest dose. Reproductive parameters were not affected. The foetuses did not show any skeletal or visceral abnormalities. The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls. It was not clear if this effect was due to direct intrauterine drug action or to a reduced body weight gain of the dams. The 24 hours survival rate of the foetuses was not affected by the treatment of the dams. Conclusion Under the study conditions, the NOAEL for maternal and developmental toxicity was set at 500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study can be considered as reliable. A NOAEL of 500 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity as there were no adverse effects on the dams or foetuses at doses of up to 500 mg/kg/day, the highest dose tested. 3rd study In a pilot prenatal developmental toxicity study according to OECD Test Guideline 414 (no information regarding GLP compliance; study period n","page":50,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_011"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/day | rat | oral | 5 days | NOAEL study | {"dose":"DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007).","effect":"s and reduced sperm count in offspring dosed during fetal development and in the postnatal period (Axelstad et al., 2011). Furthermore, at higher doses the substance induces increased uterine weight, changed uterine weight and histology, and changed gene expression in uterus in screening studies for estrogenic effect (Klammer et al., 2005; Seidlova-Wuttke et al., 2006). Estrogenic receptor activity has also been observed in cell-based studies (Seidlova- Wuttke et al., 2006). DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007). Other rat studies show a corresponding effect on T4 levels after OMC dosing of pregnant (Axelstad 2011) and ovariectomized female rats, respectively (Seidlova-Wuttke et al., 2006). Furthermore, OMC has been shown to affect the deiodinase enzyme activity in the liver. This mechanism is one of the ways in which thyroid disrupting chemical substances may affect the thyroid hormone system. The","page":80,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_014"} |
| SCCS_vision_codex | NOAEL | =10 | % | rat | oral | 13 weeks | repeated dose toxicity | {"dose":"As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used.","effect":".1 (0.45%). As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used. As EHMC is considered to be extensively absorbed by oral route, the NOAEL is not adjusted for oral bioavailability (see section 3.2.2). Following MoS calculations for separate product types and aggregated exposure (see table 9 above) can be calculated: Product type SED Total (mg/kg bw/day) NOAEL (mg/kg bw/day) MoS Dermal exposure: Sunscreen lotion 0.135 450 3333 Face cream* 0.012 450 37500 Hand cream* 0.016 450 28125 Oral exposure: Lip stick* 0.09 450 5000 Inhalatory exposure: Sunscreen propellant spray* 0.311 450 1447 Sunscreen pump spray 0.137 450 3285 Overall aggregate* (deterministic) 0.429 450 1049 Considering the different cosmetic products either directly applied on the skin or by spray, at the maximum concentration of 10% EHMC, taken individually and also the aggregated exposure, the Mo","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_017"} |
| SCCS_vision_codex | NOAEL | =85 | - | - | - | - | NOAEL study | {"dose":"Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","effect":"Unlabeled table on page 85: Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_020"} |
| SCCS_vision_codex | NOAEL | =900 | mg/kg bw/day | rat | dermal | - | NOAEL study | {"dose":"Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats.","effect":"SCCS-rejected applicant NOAEL: SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 43 decrease in the absolute weight of the heart. Further, increases in the absolute weight of the pituitary were observed at the lower doses but these were not considered to be biologically significant. Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study). Dermal exposure 1st study Guideline: No guideline Species/strain: Rabbits/ New Zealand White Group size: 5/sex/group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: Not specified Route: Dermal Administration: Occ","page":43,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_001"} |
| SCCS_vision_codex | NOAEL | =1500 | mg/kg bw/day | rat | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day.","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study is considered as reliable with restrictions as the top two doses exceeded the recommended limit dose of 1000 mg/kg/day. 2nd study Guideline: Similar to OECD Test Guideline 410 Species/strain: Rats/Sprague-Dawley Group size: 5/ sex/ group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: 0, 0.5,","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_002"} |
| SCCS_vision_codex | NOAEL | =5000 | mg/kg bw/day | - | dermal | - | NOAEL study | {"dose":"This was dose dependent and appeared to be more prominent in males.","effect":"mals were sacrificed and macroscopically examined, organs were weighed, and comprehensive histopathology was performed. Results No mortalities and no treatment related systemic effects were observed. No effects were noted at necropsy in any of the tissues or organs evaluated. All animals displayed low grade epidermal proliferation. This was dose dependent and appeared to be more prominent in males. Dermal inflammatory or fibrotic responses were not significant. Conclusion Under the conditions of the study, the NOAEL for EHMC was established by the study authors at 5000 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017)","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_003"} |
| SCCS_vision_codex | NOAEL | =450 | mg/kg bw/day | - | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021;","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021; NICNAS, 2017) SCCS comment The range of investigations was consistent with the version of the OECD TG at the time the study was conducted, including gross and histopathological examination of the thyroid gland. No treatment-related changes were reported for food consumption, body weight, body weight gain or mortalities. This study is considered as reliable. A NOAEL of 450 mg/kg bw/day based on reduction of the glycogen content and shrinkage of hepatocytes at a dose of 1","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_004"} |
| SCCS_vision_codex | NOAEL | =555 | mg/kg bw/day | - | inhalation | 5 days | NOAEL study | {"dose":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks.","effect":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks. Results No mortalities were observed. Slight scaliness of the skin (attributed to the vehicle) was observed at the application sites for all animals. At the highest dose, elevated (but non- significant) serum alanine phosphatase (SAP) levels and increased relative liver weights were observed. Liver effects were not observable upon microscopic examination. There were no changes in haematological parameters. Conclusion The study investigators established the NOAEL for EHMC at 555 mg/kg bw/day. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study, exposure is not continuous…) Inhalation route No inhalation studies on EHMC could be identified.","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_006"} |
| SCCS_vision_codex | NOAEL | =1000 | mg/kg bw/day | - | - | developmental | developmental toxicity | {"dose":"Slight reduction in the body weight was observed at the highest dose.","effect":"emales during the study. Slight reduction in the body weight was observed at the highest dose. Skeletal variation was seen to be increased. Conclusion Under the study conditions, the test substance was not teratogenic up to highest tested dose of 1000 mg/kg bw/day. (SCC, 2000) SCCS comment In the Evaluation Conclusion Document (2017) this study is described in more detail (Vehicle: 5% Carboxymethylcellulose, 0.5% Benzyl-EtOH, 0.4% TWEEN 80, 0.9% NaCl), which better demonstrates the reliability of the results. A NOAEL of 1000 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity, as no effects were observed at the highest dose.","page":49,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_010"} |
| SCCS_vision_codex | NOAEL | =500 | mg/kg bw/day | - | - | developmental | reproductive toxicity | {"dose":"The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls.","effect":"the highest dose. Reproductive parameters were not affected. The foetuses did not show any skeletal or visceral abnormalities. The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls. It was not clear if this effect was due to direct intrauterine drug action or to a reduced body weight gain of the dams. The 24 hours survival rate of the foetuses was not affected by the treatment of the dams. Conclusion Under the study conditions, the NOAEL for maternal and developmental toxicity was set at 500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study can be considered as reliable. A NOAEL of 500 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity as there were no adverse effects on the dams or foetuses at doses of up to 500 mg/kg/day, the highest dose tested. 3rd study In a pilot prenatal developmental toxicity study according to OECD Test Guideline 414 (no information regarding GLP compliance; study period n","page":50,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_011"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/day | rat | oral | 5 days | NOAEL study | {"dose":"DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007).","effect":"s and reduced sperm count in offspring dosed during fetal development and in the postnatal period (Axelstad et al., 2011). Furthermore, at higher doses the substance induces increased uterine weight, changed uterine weight and histology, and changed gene expression in uterus in screening studies for estrogenic effect (Klammer et al., 2005; Seidlova-Wuttke et al., 2006). Estrogenic receptor activity has also been observed in cell-based studies (Seidlova- Wuttke et al., 2006). DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007). Other rat studies show a corresponding effect on T4 levels after OMC dosing of pregnant (Axelstad 2011) and ovariectomized female rats, respectively (Seidlova-Wuttke et al., 2006). Furthermore, OMC has been shown to affect the deiodinase enzyme activity in the liver. This mechanism is one of the ways in which thyroid disrupting chemical substances may affect the thyroid hormone system. The","page":80,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_014"} |
| SCCS_vision_codex | NOAEL | =10 | % | rat | oral | 13 weeks | repeated dose toxicity | {"dose":"As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used.","effect":".1 (0.45%). As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used. As EHMC is considered to be extensively absorbed by oral route, the NOAEL is not adjusted for oral bioavailability (see section 3.2.2). Following MoS calculations for separate product types and aggregated exposure (see table 9 above) can be calculated: Product type SED Total (mg/kg bw/day) NOAEL (mg/kg bw/day) MoS Dermal exposure: Sunscreen lotion 0.135 450 3333 Face cream* 0.012 450 37500 Hand cream* 0.016 450 28125 Oral exposure: Lip stick* 0.09 450 5000 Inhalatory exposure: Sunscreen propellant spray* 0.311 450 1447 Sunscreen pump spray 0.137 450 3285 Overall aggregate* (deterministic) 0.429 450 1049 Considering the different cosmetic products either directly applied on the skin or by spray, at the maximum concentration of 10% EHMC, taken individually and also the aggregated exposure, the Mo","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_017"} |
| SCCS_vision_codex | NOAEL | =85 | - | - | - | - | NOAEL study | {"dose":"Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","effect":"Unlabeled table on page 85: Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_020"} |
| SCCS_vision_codex | NOAEL | =900 | mg/kg bw/day | rat | dermal | - | NOAEL study | {"dose":"Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats.","effect":"SCCS-rejected applicant NOAEL: SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 43 decrease in the absolute weight of the heart. Further, increases in the absolute weight of the pituitary were observed at the lower doses but these were not considered to be biologically significant. Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study). Dermal exposure 1st study Guideline: No guideline Species/strain: Rabbits/ New Zealand White Group size: 5/sex/group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: Not specified Route: Dermal Administration: Occ","page":43,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_001"} |
| SCCS_vision_codex | NOAEL | =1500 | mg/kg bw/day | rat | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day.","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study is considered as reliable with restrictions as the top two doses exceeded the recommended limit dose of 1000 mg/kg/day. 2nd study Guideline: Similar to OECD Test Guideline 410 Species/strain: Rats/Sprague-Dawley Group size: 5/ sex/ group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: 0, 0.5,","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_002"} |
| SCCS_vision_codex | NOAEL | =5000 | mg/kg bw/day | - | dermal | - | NOAEL study | {"dose":"This was dose dependent and appeared to be more prominent in males.","effect":"mals were sacrificed and macroscopically examined, organs were weighed, and comprehensive histopathology was performed. Results No mortalities and no treatment related systemic effects were observed. No effects were noted at necropsy in any of the tissues or organs evaluated. All animals displayed low grade epidermal proliferation. This was dose dependent and appeared to be more prominent in males. Dermal inflammatory or fibrotic responses were not significant. Conclusion Under the conditions of the study, the NOAEL for EHMC was established by the study authors at 5000 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017)","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_003"} |
| SCCS_vision_codex | NOAEL | =450 | mg/kg bw/day | - | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021;","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021; NICNAS, 2017) SCCS comment The range of investigations was consistent with the version of the OECD TG at the time the study was conducted, including gross and histopathological examination of the thyroid gland. No treatment-related changes were reported for food consumption, body weight, body weight gain or mortalities. This study is considered as reliable. A NOAEL of 450 mg/kg bw/day based on reduction of the glycogen content and shrinkage of hepatocytes at a dose of 1","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_004"} |
| SCCS_vision_codex | NOAEL | =555 | mg/kg bw/day | - | inhalation | 5 days | NOAEL study | {"dose":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks.","effect":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks. Results No mortalities were observed. Slight scaliness of the skin (attributed to the vehicle) was observed at the application sites for all animals. At the highest dose, elevated (but non- significant) serum alanine phosphatase (SAP) levels and increased relative liver weights were observed. Liver effects were not observable upon microscopic examination. There were no changes in haematological parameters. Conclusion The study investigators established the NOAEL for EHMC at 555 mg/kg bw/day. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study, exposure is not continuous…) Inhalation route No inhalation studies on EHMC could be identified.","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_006"} |
| SCCS_vision_codex | NOAEL | =1000 | mg/kg bw/day | - | - | developmental | developmental toxicity | {"dose":"Slight reduction in the body weight was observed at the highest dose.","effect":"emales during the study. Slight reduction in the body weight was observed at the highest dose. Skeletal variation was seen to be increased. Conclusion Under the study conditions, the test substance was not teratogenic up to highest tested dose of 1000 mg/kg bw/day. (SCC, 2000) SCCS comment In the Evaluation Conclusion Document (2017) this study is described in more detail (Vehicle: 5% Carboxymethylcellulose, 0.5% Benzyl-EtOH, 0.4% TWEEN 80, 0.9% NaCl), which better demonstrates the reliability of the results. A NOAEL of 1000 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity, as no effects were observed at the highest dose.","page":49,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_010"} |
| SCCS_vision_codex | NOAEL | =500 | mg/kg bw/day | - | - | developmental | reproductive toxicity | {"dose":"The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls.","effect":"the highest dose. Reproductive parameters were not affected. The foetuses did not show any skeletal or visceral abnormalities. The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls. It was not clear if this effect was due to direct intrauterine drug action or to a reduced body weight gain of the dams. The 24 hours survival rate of the foetuses was not affected by the treatment of the dams. Conclusion Under the study conditions, the NOAEL for maternal and developmental toxicity was set at 500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study can be considered as reliable. A NOAEL of 500 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity as there were no adverse effects on the dams or foetuses at doses of up to 500 mg/kg/day, the highest dose tested. 3rd study In a pilot prenatal developmental toxicity study according to OECD Test Guideline 414 (no information regarding GLP compliance; study period n","page":50,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_011"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/day | rat | oral | 5 days | NOAEL study | {"dose":"DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007).","effect":"s and reduced sperm count in offspring dosed during fetal development and in the postnatal period (Axelstad et al., 2011). Furthermore, at higher doses the substance induces increased uterine weight, changed uterine weight and histology, and changed gene expression in uterus in screening studies for estrogenic effect (Klammer et al., 2005; Seidlova-Wuttke et al., 2006). Estrogenic receptor activity has also been observed in cell-based studies (Seidlova- Wuttke et al., 2006). DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007). Other rat studies show a corresponding effect on T4 levels after OMC dosing of pregnant (Axelstad 2011) and ovariectomized female rats, respectively (Seidlova-Wuttke et al., 2006). Furthermore, OMC has been shown to affect the deiodinase enzyme activity in the liver. This mechanism is one of the ways in which thyroid disrupting chemical substances may affect the thyroid hormone system. The","page":80,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_014"} |
| SCCS_vision_codex | NOAEL | =10 | % | rat | oral | 13 weeks | repeated dose toxicity | {"dose":"As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used.","effect":".1 (0.45%). As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used. As EHMC is considered to be extensively absorbed by oral route, the NOAEL is not adjusted for oral bioavailability (see section 3.2.2). Following MoS calculations for separate product types and aggregated exposure (see table 9 above) can be calculated: Product type SED Total (mg/kg bw/day) NOAEL (mg/kg bw/day) MoS Dermal exposure: Sunscreen lotion 0.135 450 3333 Face cream* 0.012 450 37500 Hand cream* 0.016 450 28125 Oral exposure: Lip stick* 0.09 450 5000 Inhalatory exposure: Sunscreen propellant spray* 0.311 450 1447 Sunscreen pump spray 0.137 450 3285 Overall aggregate* (deterministic) 0.429 450 1049 Considering the different cosmetic products either directly applied on the skin or by spray, at the maximum concentration of 10% EHMC, taken individually and also the aggregated exposure, the Mo","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_017"} |
| SCCS_vision_codex | NOAEL | =85 | - | - | - | - | NOAEL study | {"dose":"Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","effect":"Unlabeled table on page 85: Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_020"} |
| SCCS_vision_codex | NOAEL | =900 | mg/kg bw/day | rat | dermal | - | NOAEL study | {"dose":"Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats.","effect":"SCCS-rejected applicant NOAEL: SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 43 decrease in the absolute weight of the heart. Further, increases in the absolute weight of the pituitary were observed at the lower doses but these were not considered to be biologically significant. Conclusion The study investigators established the NOAEL for EHMC 900 mg/kg bw/day in rats. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study). Dermal exposure 1st study Guideline: No guideline Species/strain: Rabbits/ New Zealand White Group size: 5/sex/group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: Not specified Route: Dermal Administration: Occ","page":43,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_001"} |
| SCCS_vision_codex | NOAEL | =1500 | mg/kg bw/day | rat | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day.","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 44 Conclusion Under the conditions of the study, the study investigators established the NOAEL for EHMC at 1500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study is considered as reliable with restrictions as the top two doses exceeded the recommended limit dose of 1000 mg/kg/day. 2nd study Guideline: Similar to OECD Test Guideline 410 Species/strain: Rats/Sprague-Dawley Group size: 5/ sex/ group Test substance: Ethylhexyl Methoxycinnamate Batch: Not specified Purity: Not specified Vehicle: No vehicle Dose levels: 0, 500, 1500 or 5000 mg/kg bw/day Dose volume: 0, 0.5,","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_002"} |
| SCCS_vision_codex | NOAEL | =5000 | mg/kg bw/day | - | dermal | - | NOAEL study | {"dose":"This was dose dependent and appeared to be more prominent in males.","effect":"mals were sacrificed and macroscopically examined, organs were weighed, and comprehensive histopathology was performed. Results No mortalities and no treatment related systemic effects were observed. No effects were noted at necropsy in any of the tissues or organs evaluated. All animals displayed low grade epidermal proliferation. This was dose dependent and appeared to be more prominent in males. Dermal inflammatory or fibrotic responses were not significant. Conclusion Under the conditions of the study, the NOAEL for EHMC was established by the study authors at 5000 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017)","page":44,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_003"} |
| SCCS_vision_codex | NOAEL | =450 | mg/kg bw/day | - | - | - | NOAEL study | {"dose":"226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021;","effect":"SCCS/1671/24 Final version Opinion on Ethylhexyl Methoxycinnamate (EHMC) (CAS No. 5466-77-3/83834-59-7, EC No. 226-775-7/629-661-9 _________________________________________________________________________________ 46 Conclusion The study investigators established the NOAEL for EHMC at 450 mg/kg bw/day (ECHA, 2021; NICNAS, 2017) SCCS comment The range of investigations was consistent with the version of the OECD TG at the time the study was conducted, including gross and histopathological examination of the thyroid gland. No treatment-related changes were reported for food consumption, body weight, body weight gain or mortalities. This study is considered as reliable. A NOAEL of 450 mg/kg bw/day based on reduction of the glycogen content and shrinkage of hepatocytes at a dose of 1","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_004"} |
| SCCS_vision_codex | NOAEL | =555 | mg/kg bw/day | - | inhalation | 5 days | NOAEL study | {"dose":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks.","effect":"55.5, 277 or 555 mg/kg bw/day, 5 days/week for 13 weeks. Results No mortalities were observed. Slight scaliness of the skin (attributed to the vehicle) was observed at the application sites for all animals. At the highest dose, elevated (but non- significant) serum alanine phosphatase (SAP) levels and increased relative liver weights were observed. Liver effects were not observable upon microscopic examination. There were no changes in haematological parameters. Conclusion The study investigators established the NOAEL for EHMC at 555 mg/kg bw/day. (NICNAS, 2017; SCC, 2000) SCCS comment This study is considered of low reliability (not a guideline study, not a GLP study, exposure is not continuous…) Inhalation route No inhalation studies on EHMC could be identified.","page":46,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_006"} |
| SCCS_vision_codex | NOAEL | =1000 | mg/kg bw/day | - | - | developmental | developmental toxicity | {"dose":"Slight reduction in the body weight was observed at the highest dose.","effect":"emales during the study. Slight reduction in the body weight was observed at the highest dose. Skeletal variation was seen to be increased. Conclusion Under the study conditions, the test substance was not teratogenic up to highest tested dose of 1000 mg/kg bw/day. (SCC, 2000) SCCS comment In the Evaluation Conclusion Document (2017) this study is described in more detail (Vehicle: 5% Carboxymethylcellulose, 0.5% Benzyl-EtOH, 0.4% TWEEN 80, 0.9% NaCl), which better demonstrates the reliability of the results. A NOAEL of 1000 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity, as no effects were observed at the highest dose.","page":49,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_010"} |
| SCCS_vision_codex | NOAEL | =500 | mg/kg bw/day | - | - | developmental | reproductive toxicity | {"dose":"The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls.","effect":"the highest dose. Reproductive parameters were not affected. The foetuses did not show any skeletal or visceral abnormalities. The median individual body weight of foetuses was decreased at 500 mg/kg bw/day but was within the range of other doses and the controls. It was not clear if this effect was due to direct intrauterine drug action or to a reduced body weight gain of the dams. The 24 hours survival rate of the foetuses was not affected by the treatment of the dams. Conclusion Under the study conditions, the NOAEL for maternal and developmental toxicity was set at 500 mg/kg bw/day. (ECHA, 2021; NICNAS, 2017) SCCS comment This study can be considered as reliable. A NOAEL of 500 mg/kg bw/day can be derived for maternal toxicity and for developmental toxicity as there were no adverse effects on the dams or foetuses at doses of up to 500 mg/kg/day, the highest dose tested. 3rd study In a pilot prenatal developmental toxicity study according to OECD Test Guideline 414 (no information regarding GLP compliance; study period n","page":50,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_011"} |
| SCCS_vision_codex | NOAEL | =100 | mg/kg bw/day | rat | oral | 5 days | NOAEL study | {"dose":"DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007).","effect":"s and reduced sperm count in offspring dosed during fetal development and in the postnatal period (Axelstad et al., 2011). Furthermore, at higher doses the substance induces increased uterine weight, changed uterine weight and histology, and changed gene expression in uterus in screening studies for estrogenic effect (Klammer et al., 2005; Seidlova-Wuttke et al., 2006). Estrogenic receptor activity has also been observed in cell-based studies (Seidlova- Wuttke et al., 2006). DNEL of 1000 μg/kg bw/day is based on a NOAEL of 100 mg/kg bw/day in a study showing a decrease in T4 level in male rats dosed by gavage for 5 days (Klammer et al., 2007). Other rat studies show a corresponding effect on T4 levels after OMC dosing of pregnant (Axelstad 2011) and ovariectomized female rats, respectively (Seidlova-Wuttke et al., 2006). Furthermore, OMC has been shown to affect the deiodinase enzyme activity in the liver. This mechanism is one of the ways in which thyroid disrupting chemical substances may affect the thyroid hormone system. The","page":80,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_014"} |
| SCCS_vision_codex | NOAEL | =10 | % | rat | oral | 13 weeks | repeated dose toxicity | {"dose":"As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used.","effect":".1 (0.45%). As point of departure for risk assessment, a NOAEL of 450 mg/kg bw/day, based on a 13 weeks oral repeated dose rat study (see section 3.4.4.2) and a 2-generation reproductive toxicity (see section 3.4.5.1) is used. As EHMC is considered to be extensively absorbed by oral route, the NOAEL is not adjusted for oral bioavailability (see section 3.2.2). Following MoS calculations for separate product types and aggregated exposure (see table 9 above) can be calculated: Product type SED Total (mg/kg bw/day) NOAEL (mg/kg bw/day) MoS Dermal exposure: Sunscreen lotion 0.135 450 3333 Face cream* 0.012 450 37500 Hand cream* 0.016 450 28125 Oral exposure: Lip stick* 0.09 450 5000 Inhalatory exposure: Sunscreen propellant spray* 0.311 450 1447 Sunscreen pump spray 0.137 450 3285 Overall aggregate* (deterministic) 0.429 450 1049 Considering the different cosmetic products either directly applied on the skin or by spray, at the maximum concentration of 10% EHMC, taken individually and also the aggregated exposure, the Mo","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_017"} |
| SCCS_vision_codex | NOAEL | =85 | - | - | - | - | NOAEL study | {"dose":"Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","effect":"Unlabeled table on page 85: Product type | SED Total (mg/kg bw/day) | NOAEL (mg/kg bw/day) | MoS","page":85,"pdf":"sccs_o_294.pdf","row_type":"noael_study","study_id":"sccs_o_294_noael_020"} |
openFDA substances 12 endpoints
| Source | Endpoint Type | Value | Unit | Species | Route | Duration | Study Type | Reference |
|---|---|---|---|---|---|---|---|---|
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |
| openFDA substances | FDA UNII substance identifier | 4Y5P7MUD51 | UNII | - | - | - | chemical | {"approval_status":null,"molecular_formula":"C18H26O3","source_table":"substance_identifiers_fda","substance_class":"chemical","unii_code":"4Y5P7MUD51"} |